Unknown

Dataset Information

0

Terbium-149 production: a focus on yield and quality improvement towards preclinical application.


ABSTRACT: Terbium-149 (T1/2 = 4.1 h, Eα = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison with other α-particle emitters. In this study, terbium-149 was produced via 1.4 GeV proton irradiation of a tantalum target at the CERN-ISOLDE facility. The spallation products were mass separated and implanted on zinc-coated foils and, later, radiochemically processed. Terbium-149 was separated from the co-produced isobaric radioisotopes and the zinc coating from the implantation foil, using cation-exchange and extraction chromatographic techniques, respectively. At the end of separation, up to 260 MBq terbium-149 were obtained with > 99% radionuclidic purity. Radiolabeling experiments were performed with DOTATATE, achieving 50 MBq/nmol apparent molar activity with radiochemical purity > 99%. The chemical purity was determined by inductively coupled plasma-mass spectrometry measurements, which showed lead, copper, iron and zinc only at ppb level. The radiolabeling of the somatostatin analogue DOTATATE with [149Tb]TbCl3 and the subsequent in vivo PET/CT scans conducted in xenografted mice, showing good tumor uptake, further demonstrated product quality and its ability to be used in a preclinical setting.

SUBMITTER: Favaretto C 

PROVIDER: S-EPMC10853284 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Terbium-149 production: a focus on yield and quality improvement towards preclinical application.

Favaretto C C   Grundler P V PV   Talip Z Z   Köster U U   Johnston K K   Busslinger S D SD   Sprung P P   Hillhouse C C CC   Eichler R R   Schibli R R   Müller C C   van der Meulen N P NP  

Scientific reports 20240208 1


Terbium-149 (T<sub>1/2</sub> = 4.1 h, E<sub>α</sub> = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison with other α-particle emitters. In this study, terbium-149 was produced via 1.4 GeV proton irradiation of a tantalum target at the CERN-ISOLDE facility. The spallation products were mass separated and implanted on zinc-coate  ...[more]

Similar Datasets

| S-EPMC11650298 | biostudies-literature
| S-EPMC9291162 | biostudies-literature
| S-EPMC8620972 | biostudies-literature
| S-EPMC11852564 | biostudies-literature
| S-EPMC11552270 | biostudies-literature
| S-EPMC6086401 | biostudies-literature
| S-EPMC6435734 | biostudies-literature
| S-EPMC7103793 | biostudies-literature
| S-EPMC10994299 | biostudies-literature
| S-EPMC9318807 | biostudies-literature